SEC Gets Consent Win For CEO's COVID-19 Product Claims
By Jonathan Capriel ( April 19, 2022, 5:58 PM EDT) -- The U.S. Securities and Exchange Commission's case against a biotechnology firm and its chief executive accused of falsely claiming regulators approved of their disinfectants for fighting COVID-19 has resulted in a civil penalty and a prohibition on trading penny stocks, according to a consent judgment approved by an Ohio federal judge....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.